Center for Targeted Therapeutics

靶向治疗中心

• 批准号: 10221696
• 负责人: IGOR B RONINSON
• 金额: $ 223.5万
• 依托单位: UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-10 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10221696
• 关键词: Address; Alzheimer' s Disease; Applications Grants; Area; Automobile Driving; Award; Biology; Career Mobility; Cellular biology; Centers of Research Excellence; Chemicals; Collaborations; Complement; Core Facility; Databases; Development; Developmental Biology; Disease; Drug Compounding; Drug Design; Economic Development; Education; Educational workshop; Environment; Equipment; Faculty; Financial Support; Flow Cytometry; Fostering; Friends; Funding; Future; Goals; Grant; Interdisciplinary Study; Laboratories; Malignant Neoplasms; Medical; Mentors; Microscopy; Mission; Molecular Target; Paper; Pharmaceutical Preparations; Pharmacotherapy; Phase; Pilot Projects; Play; Process; Public Health; Publishing; Reporting; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Support; Resource Sharing; Resources; Scientist; Senior Scientist; Services; Small Business Innovation Research Grant; Small Business Technology Transfer Research; South Carolina; Structure; Talents; Technology; Therapeutic; Therapeutic Human Experimentation; Training; United States National Institutes of Health; Universities; Vision; Work; cancer genomics; career development; cellular targeting; college; common treatment; drug discovery; drug synthesis; faculty mentor; functional genomics; high risk; infrastructure development; instrumentation; interest; meetings; member; multidisciplinary; new therapeutic target; next generation; operation; programs; prototype; recruit; research and development; senior faculty; success; targeted treatment; tenure track

ABSTRACT The principal Phase II goal of the COBRE Center for Targeted Therapeutics (CTT) is to conduct vital research oriented at identifying novel drug targets and discovering new targeted drugs, while enhancing the career development and research competitiveness of Center investigators. Targeted therapeutics is a broad term for research that seeks to develop new and more effective classes of drugs against various diseases, by selectively aiming these drugs at molecular and cellular targets that play a key role in the disease. The area of Targeted Therapeutics has been chosen because of its societal impact, the emergence of common technologies driving therapeutics research in different disease areas, and the presence of a critical core of senior faculty with broad acumen and trans-disciplinary vision in Targeted Therapeutics at USC. During Phase I, junior investigators leading CTT research projects (target PIs) were awarded five R01s and several smaller grants, and pilot project recipients received two R01s and several other grants, for a total of close to $14 million. Four target PIs received promotion and tenure and almost 50 published papers acknowledged COBRE support. Three resource cores established by the CTT provided services to 64 different laboratories and organized training workshops and a new graduate course. To build upon the success of Phase I, we will pursue the following Specific Aims. Aim 1. Support high-impact research projects and assist junior scientists in Targeted Therapeutics in their professional development and competitiveness for NIH grants, in a collaborative and nurturing environment. Target junior faculty members include four highly promising scientists, each of whom will be mentored by two senior scientists with different areas of expertise relevant to their research. Aim 2. Establish sustainable research infrastructure through the further development of strategic Cores for Targeted Therapeutics research. The Center supports research cores in Functional Genomics, Drug Design and Synthesis, and Microscopy and Flow Cytometry. These cores will provide both specialized services and intellectual scientific support. Aim 3. Assure long-term development of the CTT by broadening collaborative networking, fostering continuous recruitment, supporting new faculty in Targeted Therapeutics, and supporting pilot research projects, with an emphasis on drug discovery and preparation for multi-investigator and SBIR/STTR grant applications. CTT will conduct regular meetings and seminars and promote external collaborations. CTT will participate in the recruitment of five new junior faculty members to USC and will continue working with the “graduated” target faculty, assuring that they continue to make important discoveries and win grants. Continued success of the CTT will make an impact on the public health, scientific education and economic development of the State.

摘要 科布雷靶向治疗中心(CTT)的主要第二阶段目标是进行重要研究 致力于发现新的药物靶点和发现新的靶向药物，同时促进职业生涯 中心研究人员的开发和研究竞争力。靶向治疗是一个宽泛的术语，指 寻求开发新的和更有效的药物类别来对抗各种疾病的研究，通过选择性地 将这些药物瞄准在疾病中发挥关键作用的分子和细胞靶点。目标区域 选择治疗学是因为它的社会影响，共同技术的出现推动了 不同疾病领域的治疗学研究，以及具有广泛经验的关键核心高级教员的存在 南加州大学靶向治疗中的敏锐和跨学科视野。在第一阶段，初级调查员 领先的CTT研究项目(目标绩效指标)获得了五个R01和几个较小的赠款，以及试点项目 获奖者获得了两个R01和其他几个赠款，总额接近1400万美元。已收到四个目标PI 晋升和终身教职以及发表的近50篇论文都承认了科布雷的支持。三个资源核 成立了CTT，为提供了不同的实验室，并组织了培训讲习班和 新的研究生课程。为了在第一阶段取得成功的基础上再接再厉，我们将实现以下具体目标。 目标1.支持高影响力的研究项目，并协助初级科学家进行靶向治疗 在协作和培育的环境中，为NIH赠款提供专业发展和竞争力。 目标初级教员包括四名非常有前途的科学家，他们每人将得到两名指导 具有与其研究相关的不同专业领域的资深科学家。 目标2.通过进一步发展战略核心，建立可持续的研究基础设施 靶向治疗研究。该中心支持功能基因组学、药物设计和 合成，显微镜和流式细胞术。这些核心将提供专门的服务和 智力科学支持。 目标3.通过扩大协作网络，促进持续发展，确保反恐委员会的长期发展 招聘，支持靶向治疗领域的新教师，并支持试点研究项目， 强调药物的发现和准备，以供多名研究人员和SBIR/STTR赠款申请。CTT将 定期召开会议和研讨会，促进外部合作。CTT将参加 为南加州大学招聘五名新的初级教员，并将继续实现“毕业”的目标 教师，确保他们继续做出重要发现并赢得拨款。CTT继续取得成功 将对国家的公共健康、科学教育和经济发展产生影响。